Abstract
Depression is a widely prevalent psychiatric illness with variable levels of severity that necessitate different approaches to treatment. To enhance the management of this condition, there is a growing interest in utilizing mobile devices, especially smartphones, for remote monitoring of patients. This study aims to build prediction models for depression severity based on active and passive features collected from patients with major depressive disorder (MDD) and healthy controls to assess the feasibility of remote monitoring of depression severity.
Using data from 142 participants (85 healthy controls, 67 MDD) we extracted features such as GPS-derived mobility markers, ecological momentary assessments (EMA), age, and sex to develop machine learning models of depression severity on the different diagnostic subgroups in this cohort.
Our results indicate that the employed models outperformed baseline estimators in random split scenarios. However, the improvement was marginal in user-split scenarios, highlighting the need for larger and more diverse samples for clinical utility. Among the features, mood EMA emerged as the most influential predictor, followed by GPS-derived mobility features. Models also showed a significant association between depression severity and average reported mood, as well as GPS-derived mobility markers such as number of places visited and percent home.
While predicting composite depression scores is important, future studies could explore predicting individual symptom items or symptom groups for a more comprehensive assessment of depression severity. Challenges for clinical utility include participant dropout, which could be addressed through more engaging app design to promote user adherence. Harmonization of phone-derived measures is also crucial to facilitate model transfer across studies.
In conclusion, this study contributes valuable evidence supporting the potential utility of smartphone data for mood state monitoring and predicting depression severity. Future research should focus on predicting depression further ahead in time and addressing the challenges identified to create more robust and effective depression monitoring solutions using smartphone-based data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was in part provided by grants from the German Science Foundation (DFG): Project number 44541416-TRR 58 (CRC-TRR58, Projects C09 and Z02 to Udo Dannlowski). Further DFG funding as part of Forschungsgruppe/Research Unit FOR2107 was received by: Tilo Kircher (speaker FOR2107; DFG grant numbers KI 588/14-1, KI 588/14-2, KI 588/15-1, KI 588/17-1), Udo Dannlowski (co-speaker FOR2107; DA 1151/5-1, DA 1151/5-2, DA 1151/6-1), Axel Krug (KR 3822/5-1, KR 3822/7-2), Igor Nenadic (NE 2254/1-2, NE 2254/2-1, NE 2254/3-1, NE 2254/4-1), Carsten Konrad (KO 4291/3-1), Marcella Rietschel (RI 908/11-1, RI 908/11-2), Markus Noethen (NO 246/10-1, NO 246/10-2), Stephanie Witt (WI 3439/3-1, WI 3439/3-2), Andreas Jansen (JA 1890/7-1, JA 1890/7-2), Tim Hahn (HA 7070/2-2, HA7070/3, HA7070/4), Bertram Mueller-Myhsok (MU1315/8-2), Astrid Dempfle (DE 1614/3-1, DE 1614/3-2), Petra Pfefferle (PF 784/1-1, PF 784/1-2), Harald Renz (RE 737/20-1, 737/20-2), Carsten Konrad (KO 4291/4-1). Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Muenster provided funding to Udo Dannlowski (Grant Dan3/012/17) and Nils Opel (SEED 11/19) "Innovative Medizinische Forschung" (IMF) of the medical faculty of Muenster provided funding to Elisabeth J. Leehr (Grant LE121703 and LE121904), Nils Opel and Tim Hahn (Grant OP121710).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Westfaelischen Wilhelms-Universitaet, Muenster, Germany gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
As data was derived from multiple study protocols with different limitations, the potential sharing of data would need to be discussed and evaluated on a case-by-case basis with the senior authors and different study leaders
